The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Johnsen, A. K.
Right arrow Articles by Harding, C. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Johnsen, A. K.
Right arrow Articles by Harding, C. V.
The Journal of Immunology, 1999, 163: 4224-4231.
Copyright © 1999 by The American Association of Immunologists

Deficiency of Transporter for Antigen Presentation (TAP) in Tumor Cells Allows Evasion of Immune Surveillance and Increases Tumorigenesis1

A. K. Johnsen, D. J. Templeton, M.-S. Sy and C. V. Harding2

Department of Pathology, Case Western Reserve University, Cleveland, OH 44106

Proteins involved in class I MHC (MHC-I) Ag processing, such as the TAP, are deficient in some human tumor cells. This suggests that antitumor responses by CD8 T cells provide selection pressure to favor outgrowth of cells with defective processing of tumor Ags. Nonetheless, this evidence is only correlative, and controlled in vivo experiments have been lacking to demonstrate that TAP deficiency promotes survival of tumor cells. To explore the role of Ag processing defects in tumor progression, matched panels of TAP1-positive and TAP1-negative tumor cell lines were generated from a parental transformed murine fibroblast line. Inoculation of C57BL/6 mice with TAP1-negative cells produced large and persistent tumors. In contrast, TAP1-positive cells did not generate lasting tumors, although small tumors were detected transiently and regressed spontaneously. Both TAP1-positive and TAP1-negative cells produced tumors in athymic mice, confirming that TAP-dependent differences in tumorigenicity were due to T cell-dependent immune responses. Inoculation of C57BL/6 mice with mixtures of TAP1-positive and TAP1-negative cells produced tumors composed exclusively of TAP1-negative cells, indicating in vivo selection for cells with TAP deficiency. Thus, loss of TAP function allows some tumor cells to avoid T cell-dependent elimination, resulting in selection for tumor cells with deficient Ag processing.




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
S. S. Tykodi, N. Fujii, N. Vigneron, S. M. Lu, J. K. Mito, M. X. Miranda, J. Chou, L. N. Voong, J. A. Thompson, B. M. Sandmaier, et al.
C19orf48 Encodes a Minor Histocompatibility Antigen Recognized by CD8+ Cytotoxic T Cells from Renal Cell Carcinoma Patients
Clin. Cancer Res., August 15, 2008; 14(16): 5260 - 5269.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
L. Y. Han, M. S. Fletcher, D. L. Urbauer, P. Mueller, C. N. Landen, A. A. Kamat, Y. G. Lin, W. M. Merritt, W. A. Spannuth, M. T. Deavers, et al.
HLA Class I Antigen Processing Machinery Component Expression and Intratumoral T-Cell Infiltrate as Independent Prognostic Markers in Ovarian Carcinoma
Clin. Cancer Res., June 1, 2008; 14(11): 3372 - 3379.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
A. F. Setiadi, M. D. David, R. P. Seipp, J. A. Hartikainen, R. Gopaul, and W. A. Jefferies
Epigenetic Control of the Immune Escape Mechanisms in Malignant Carcinomas
Mol. Cell. Biol., November 15, 2007; 27(22): 7886 - 7894.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
B. Chambers, P. Grufman, V. Fredriksson, K. Andersson, M. Roseboom, S. Laban, M. Camps, E. Z. Wolpert, E. J.H.J. Wiertz, R. Offringa, et al.
Induction of Protective CTL Immunity against Peptide Transporter TAP-Deficient Tumors through Dendritic Cell Vaccination
Cancer Res., September 15, 2007; 67(18): 8450 - 8455.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Y. Lou, T. Z. Vitalis, G. Basha, B. Cai, S. S. Chen, K. B. Choi, A. P. Jeffries, W. M. Elliott, D. Atkins, B. Seliger, et al.
Restoration of the Expression of Transporters Associated with Antigen Processing in Lung Carcinoma Increases Tumor-Specific Immune Responses and Survival
Cancer Res., September 1, 2005; 65(17): 7926 - 7933.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S. K. Dissanayake, N. Tuera, and S. Ostrand-Rosenberg
Presentation of Endogenously Synthesized MHC Class II-Restricted Epitopes by MHC Class II Cancer Vaccines Is Independent of Transporter Associated with Ag Processing and the Proteasome
J. Immunol., February 15, 2005; 174(4): 1811 - 1819.
[Abstract] [Full Text] [PDF]


Home page
Br J OphthalmolHome page
S Krishnakumar, S A Lakshmi, D Abhyankar, and J Biswas
Transporter associated protein expression in uveal melanoma
Br J Ophthalmol, July 1, 2004; 88(7): 925 - 928.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. E. Ohm, D. I. Gabrilovich, G. D. Sempowski, E. Kisseleva, K. S. Parman, S. Nadaf, and D. P. Carbone
VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression
Blood, June 15, 2003; 101(12): 4878 - 4886.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
C. I. Fine, C. D. Han, X. Sun, Y. Liu, and J. A. McCutcheon
Tobacco Reduces Membrane HLA Class I That Is Restored by Transfection with Transporter Associated with Antigen Processing 1 cDNA
J. Immunol., November 15, 2002; 169(10): 6012 - 6019.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
H. Furukawa, K. Iizuka, J. Poursine-Laurent, N. Shastri, and W. M. Yokoyama
A Ligand for the Murine NK Activation Receptor Ly-49D: Activation of Tolerized NK Cells from {beta}2-Microglobulin- Deficient Mice
J. Immunol., July 1, 2002; 169(1): 126 - 136.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
F. H. Igney and P. H. Krammer
Immune escape of tumors: apoptosis resistance and tumor counterattack
J. Leukoc. Biol., June 1, 2002; 71(6): 907 - 920.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Z. Qin, C. Harders, X. Cao, C. Huber, T. Blankenstein, and B. Seliger
Increased Tumorigenicity, but Unchanged Immunogenicity, of Transporter for Antigen Presentation 1-deficient Tumors
Cancer Res., May 1, 2002; 62(10): 2856 - 2860.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
B. Lankat-Buttgereit and R. Tampe
The Transporter Associated With Antigen Processing: Function and Implications in Human Diseases
Physiol Rev, January 1, 2002; 82(1): 187 - 204.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
M. J. de Veer, M. Holko, M. Frevel, E. Walker, S. Der, J. M. Paranjape, R. H. Silverman, and B. R. G. Williams
Functional classification of interferon-stimulated genes identified using microarrays
J. Leukoc. Biol., June 1, 2001; 69(6): 912 - 920.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
D. J. Nelson, S. Mukherjee, C. Bundell, S. Fisher, D. van Hagen, and B. Robinson
Tumor Progression Despite Efficient Tumor Antigen Cross-Presentation and Effective "Arming" of Tumor Antigen-Specific CTL
J. Immunol., May 1, 2001; 166(9): 5557 - 5566.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1999 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1999 by The American Association of Immunologists, Inc. All rights reserved.